Kidney disease

Nov. 14, 2026International urology and nephrologyDiabetesKidney disease

Efficacy and safety of finerenone in non-diabetic chronic kidney disease

a systematic review and meta-analysis.

A systematic review and meta-analysis demonstrates that finerenone significantly slows eGFR decline in patients with non-diabetic chronic kidney disease (difference in slope +0.70 mL/min/1.73m²/year…

Nov. 10, 2026Critical pathways in cardiologyKidney diseaseObesity

Semaglutide and Cardiovascular Death

a Systematic Review and Meta-Analysis Cardioprotective Efficacy of Semaglutide.

This meta-analysis of seven RCTs involving 38,412 patients evaluated the impact of semaglutide on cardiovascular mortality across type 2 diabetes, overweight/obesity, and HFpEF populations…

Nov. 9, 2026Cardiology researchKidney diseaseThrombosis

Warfarin After Seven Decades

Persistent Value and the Contemporary Role of Vitamin K Antagonism.

This narrative review outlines the contemporary indications for vitamin K antagonists (VKAs) in cardiovascular practice. While DOACs have largely replaced warfarin for atrial fibrillation, VKAs…

Nov. 8, 2026MedCommKidney diseaseObesity

Associations of Coexisting Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia-Related Abnormalities With Adverse Clinical Outcomes Across Obesity States.

In a prospective UK Biobank cohort of 438,748 participants, researchers evaluated the joint impact of metabolic dysfunction-associated steatotic liver disease (MASLD) and sarcopenia-related…

Nov. 7, 2026New England Journal of MedicineKidney diseaseObesity

ZEUS

ziltivekimab cuts IL-6 by 76 and hsCRP by 64 percent, but heart attack, stroke and death are unchanged in 6,376 patients with atherosclerosis, kidney disease and inflammation

Presented in LBS.01 at AHA 2026 (Saturday 7 November) by Paul Ridker and published simultaneously in NEJM. ZEUS randomised 6,376 patients (3,184 ziltivekimab, 3,192 placebo; mean age 69.4, 27.5…

Nov. 2, 2026Journal of cardiac failureKidney diseasePrimary care

Practical Prevention of Heart Failure Across Stages A and B

A Scientific Statement From the Japanese Heart Failure Society.

The Japanese Heart Failure Society issues a scientific statement outlining practical prevention strategies for heart failure in asymptomatic stages A and B. The guidance emphasizes biomarker-driven…

Nov. 2, 2026JAMADiabetesKidney disease

Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis

A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

A meta-analysis of 85 randomized trials (70,543 participants) demonstrates that SGLT2 inhibitors produce a small but statistically significant increase in hemoglobin (+0.60 g/dl) and hematocrit…

Oct. 29, 2026Journal of cardiovascular pharmacologyDiabetesKidney disease

Finerenone

A Non-Steroidal Mineralocorticoid Receptor Antagonist and Its Emerging Role in Cardiovascular-Kidney-Metabolic Syndrome.

This narrative review synthesizes evidence for finerenone in cardiovascular-kidney-metabolic (CKM) syndrome, drawing on phase 3 trials including FIDELIO-DKD, FIGARO-DKD, FINEARTS-HF, and the pooled…

Oct. 29, 2026Signal transduction and targeted therapyDiabetesKidney disease

Real-world renoprotective effects of polyethylene glycol-loxenatide in type 2 diabetes

a multicenter, ambispective cohort study.

In a multicenter ambispective cohort of 3,305 patients with type 2 diabetes and chronic kidney disease, polyethylene glycol-loxenatide demonstrated significant renoprotective effects compared to…

Oct. 28, 2026Kidney internationalKidney diseaseObesity

Safety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial.

A prespecified secondary analysis of the landmark FLOW trial confirmed that once-weekly semaglutide 1.0 mg is safe and well-tolerated across the spectrum of chronic kidney disease severity in…

Oct. 27, 2026Journal of the American Society of NephrologyKidney diseaseObesity

Glucagon-Like Peptide-1 Receptor Agonists and Multi-hormone Receptor Modulators for Kidney Protection in Nondiabetic Kidney Disease.

This review examines the renal protective effects of GLP-1 receptor agonists and newer multi-hormone receptor modulators in patients with non-diabetic chronic kidney disease. Benefits arise through…

Oct. 27, 2026JAMA neurologyKidney diseaseLifestyle

Vascular Risk Factors and Late-Onset Epilepsy.

An individual participant data meta-analysis of six US prospective cohorts (n = 42,257) found that common vascular risk factors—including hypertension, diabetes, chronic kidney disease, smoking, and…